46 results on '"Castanon, Eduardo"'
Search Results
2. Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple‐negative breast cancer: Results from the triple‐negative breast cancer cohort of the phase 2 LEAP‐005 Study.
3. Critical reappraisal of phase III trials with immune checkpoint inhibitors in non-proportional hazards settings
4. Prognostic role of stress cardiac magnetic resonance in the elderly
5. Valor pronóstico de la cardiorresonancia magnética de estrés en pacientes ancianos
6. Patterns of progression in patients treated for immuno-oncology antibodies combination
7. Are phase I trials safe for older patients?
8. Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors)
9. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)
10. The inhibitor of differentiation-1 (Id1) enables lung cancer liver colonization through activation of an EMT program in tumor cells and establishment of the pre-metastatic niche
11. Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer
12. Differential Tumor Expression of Inhibitor of Differentiation-1 in Prostate Cancer Patients With Extreme Clinical Phenotypes and Prognostic Implications
13. 592 Phase 1/2a study of the novel nonfucosylated anti–CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: part 1 results
14. Safety and Efficacy of Maintenance Therapy With a Nonspecific Cytochrome P17 Inhibitor (CYP17i) After Response/Stabilization to Docetaxel in Metastatic Castration-Resistant Prostate Cancer
15. Clinical Management of Small-Cell Carcinoma of the Urinary Tract: A 10-Year Single-Center's Experience
16. Abstract CT107: Correlation of biomarkers and clinical benefit of intratumoral BO112 and pembrolizumab in patients with anti PD1 refractory melanoma
17. Does active smoking worsen Covid-19?
18. Combination of radiomic and biomarker signatures as exploratory objective in a phase II trial with intratumoral BO-112 plus pembrolizumab for advanced melanoma.
19. Abstract PS12-07: Lenvatinib plus pembrolizumab for previously treated, advanced triple-negative breast cancer: Early results from the multicohort phase 2 LEAP-005 study
20. Patterns of progression in patients treated for immuno-oncology antibodies combination
21. Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types
22. Endoscopical and pathological dissociation in severe colitis induced by immune-checkpoint inhibitors
23. MET Receptor Amplification Drives Resistance to Anti-EGFR Therapies
24. Neoadjuvant therapy for locally advanced gastric cancer patients. A population pharmacodynamic modeling
25. Clinical features and short-term outcomes of cancer patients with suspected and unsuspected pulmonary embolism: the EPIPHANY study
26. Erratum to “Critical reappraisal of phase III trials with immune checkpoint inhibitors in non-proportional hazards settings” [Eur J Cancer 136 (September 2020) 159−168]
27. Dinámica de la inflación: un análisis econométrico del ajuste heterodoxo mexicano
28. Take-home message in times of crisis: Is it really better to treat with cisplatin & pemetrexed than cisplatin & gemcitabine in first line NSCLC? The power of statistical considerations
29. Locally advanced cervical cancer with bladder invasion: clinical outcomes and predictive factors for vesicovaginal fistulae
30. A nomogram for predicting complications in patients with solid tumours and seemingly stable febrile neutropenia
31. Overall survival prognosis of patients in immuno-oncology phase I trials: The Gustave Roussy score.
32. Anti-PD1–Induced Pneumonitis: Capturing the Hidden Enemy
33. Epidermal Growth Factor Receptor Targeting in Non-Small Cell Lung Cancer: Revisiting Different Strategies Against the Same Target
34. A nomogram for predicting serious complications in patients with solid tumors and apparently stable febrile neutropenia: Prospective data on 781 consecutive episodes from the FINITE study.
35. Abstract 1996: Inhibitor of differentiation-1 (Id1) expression deficiency in the tumor microenvironment impairs experimental hepatic metastasis of lung cancer
36. Familial clustering of prostate cancer (Pca) cases in a nonselected south European population (sEp).
37. Oxaliplatin, irinotecan, and PK-adjusted 5-fluorouracil within a multidisciplinary approach in patients with locally advanced pancreatic cancer (LAPC): Preliminary results.
38. Preliminary results of preoperative FOLFOX chemotherapy for locally advanced colon cancer patients with therapeutic drug monitoring of 5-FU.
39. Relevance of MIA and S-100 to monitor BRAF inhibitor (iBRAF) therapy in metastatic melanoma patients.
40. EGFR-activating mutations and treatment with tyrosine-kinase inhibitors (TKI) to revert poor-prognosis (PP) associated with liver metastases (LM) in stage IV non-small cell lung cancer (NSCLC) patients (pts).
41. Thymidylate synthase (TS) polymorphisms (Pol) in buffy coat-derived genomic DNA as a clinical outcome predictor in non-Asian stage III/IV non-small cell lung cancer (NSCLC) patients (pts) receiving pemetrexed (Pem).
42. Safety and efficacy of maintenance therapy (MT) with a nonspecific cytochrome-P 17 inhibitor (CYP17i) after response/stabilization to docetaxel in metastatic castratation-resistant prostate cancer (mCRPC) patients.
43. Capítulo 16 - Biología celular del cáncer
44. Colaboradores
45. Inhibitor of Differentiation 1 (Id-1) Gene Silencing Reduces Liver Metastases Formation in a NSCLC Animal Model
46. THE TUMOR MICROENVIRONMENT EXPRESSION OF THE INHIBITOR OF DIFFERENTIATION-1 (ID1) IS DETERMINANT OF THE DEVELOPMENT OF LIVER METASTASIS FROM LUNG CANCER THROUGH GENE REGULATION OF TUMOR CELLS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.